Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

313 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-27

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN.

In this study, we would like to define the germline predisposition to MPN.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NCT06923670

Polycythemia Vera Essential Thrombocythaemia Myelofibrosis

NOT_YET_RECRUITING NA

Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities

NCT05714592

Myeloproliferative Neoplasm Optical Genome Mapping Cytogenetics +2 more

UNKNOWN NA

Familial Myeloproliferative Disorders

NCT00666289

Polycythemia Vera Essential Thrombocythemia Idiopathic Myelofibrosis

COMPLETED

Longitudinal Studies of Patient With FPDMM

NCT03854318

Inherited Hematological Diseases Rare Diseases FPDMM

RECRUITING

Investigation of the Genetics of Hematologic Diseases

NCT02720679

Leukocyte Disorder Bone Marrow Failure Syndromes Erythrocyte Disorder +10 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myeloproliferative Disease Germline Mutation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria
* Characterization of the MPN driver mutation performed at any moment before enrolment
* diagnosis of MPN made when the patient was younger than 27 years old OR at least a second case of hematologic malignancies in first or second-degree relatives